The global 3D bioprinting market size is expected to reach USD 4.2 billion by 2027, expanding at a CAGR of 17.4%, according to a new report by Grand View Research, Inc. Rising prevalence of COVID-19 cases and increasing prevalence of chronic diseases are some of the major factors contributing towards market growth.
The COVID-19 epidemic is ever increasing since it was first identified in China in December 2019. Until May 26, 2020, more than 4.8 million cases of COVID-19 were reported globally, with more than 318,465 deaths, across 185 countries and territories including all 50 states of the United States. This pandemic has fast tracked the development of vaccine and drug testing, as scientists are using newer technologies to enable safety testing in people soon after preclinical phase is completed.
In the meantime, various 3D bioprinting companies are focused on research and development of artificial tissues. With the help of U-FAB, and other bioprinting technologies, CLECELL company has created respiratory epithelium artificial tissue which will help to prevent infection and tissue injury through the use of the mucociliary elevator. This pandemic has not only affected the well-being of people, but has also affected the economy, and various other healthcare infrastructures worldwide. This has severely disrupted the medical devices and pharmaceutical supply chains across the world. In such critical situation, various 3D bioprinting companies have created a global movement to supply emergency medical equipment such as ventilators, and personal protection equipment (PPE), to the healthcare workers.
North America held the highest share of the market, accounting for about 33.1% of the market share in 2019. Increasing adoption of 3D bioprinting for the production of medical products is expected to be one of the major factors contributing to market growth in this region. Whereas, Asia Pacific is anticipated to witness increased technological development in pharmaceutical and biopharmaceutical sector.
Request a free sample copy or view report summary: 3D Bioprinting Market Report
The medical segment dominated the market with a share of 21.1% in 2019 due to the increasing investment made in R&D
The magnetic levitation segment is anticipated to witness the highest CAGR of 8.9% over the forecast period due to technological development, and increasing adoption of magnetic levitation technique by various innovators
North America dominated the market in 2019. Growing government expenditure on healthcare industry is one of the major factors driving the market in this region
Few of the key market players include 3D Systems; Organovo; CELLINK; Envision TEC; Materialise NV; Bio3D Technologies; Oceanz 3D printing & Additive Manufacturing; Solidscape; Stratasys Ltd.; and Voxeljet.
Grand View Research has segmented the global 3D bioprinting market based on technology, application, and region:
3D Bioprinting Technology Outlook (Revenue, USD Million, 2016 - 2027)
3D Bioprinting Application Outlook (Revenue, USD Million, 2016 - 2027)
Tissue and organ generation
Prosthetics and implants
Consumer/Personal Product Testing
Food and Animal Product
3D Bioprinting Regional Outlook (Revenue, USD Million, 2016 - 2027)
Middle East & Africa
List of Key Players of 3D Bioprinting Market
Organovo Holdings, Inc.
Inventia Life Science PTY LTD
Vivax Bio, LLC
Cyfuse Biomedical K.K.
3D Bioprinting Solutions
Regemat 3D S.L.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."